News

Project addresses customer demand in GMP-powered advanced therapeutics.

In an effort to strengthen supply chain, unnamed pharma company to use chain of custody application to combat an illegal global market worth up to $200 billion annually.

New site is expected to complement CDMO’s commercial production experience.

Acquisition expands company’s eCTD submission capabilities.

Latest investigation signals more scrutiny of pharmacy benefit managers and their role in treatment cost and coverage.

The deal—potentially totaling upwards of $100 million—strengthens the company’s selection of US generic prescription products.

Stats point to a 14.9% decline compared to January of last year.

Initiative intends to facilitate regulatory compliance within the pharma distribution space.

With the help of traceability, new feature prioritizes efficiency and safety, from production to patient.

Following numerous successful trial runs, vaccine production is expected to reach 700 million.

Expansion expected to increase global capacity by 75%.

Enhancements to help keep products frozen for over 144 hours, company says.

Joint venture revolves around around the use of raw materials for the development—and ultimately commercialization—of therapies.

New 25,000 square-foot facility will help grow customers’ gene therapy programs.

Site expected to support growth of advanced analytics and data science team.

Pharma sector, FMI report says, is quickly growing, due to globalization and development of low-cost medications.

Facility addition expected to increase production capacity of TNAs.

Investment helps encourage sustainability in the space, especially as it pertains to pharma, company says.

cGMP line will fill vials, syringes, and cartridges, while supporting small-scale commercial production.

Conclusion driven by various factors, including product shortages and cost pressures.

Flights from Colombia and Ecuador more than doubled during the season, resulting in exports of nearly 18,000 tons.

South Korea facility expected to provide fill-finish capabilities.

New California plant expected to streamline medicine production.

Investment expected to establish additional cGMPs, expand CDMO services.

Meanwhile, PDG issues more DSCSA guidance on data interoperability.

Joint venture expected to address pharma’s injectable drug-filling sector.

Purchase doubles staffing, adds global capabilities.

Collaboration to support biotech company’s clinical and commercial production efforts.